Tarsons Products Limited has completed an equity investment of EUR 300,000 in its wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., located in Singapore. This investment follows a previous intimation on February 06, 2026, regarding a planned equity infusion of EUR 3,000,000. The company subscribed to 100 equity shares at a nominal value of EUR 3,000 per share. These funds will be utilized by the subsidiary for quarterly loan repayments to a Singaporean bank, associated interest payments, and general corporate purposes, including operational and financial expenses. Tarsons Life Science Pte. Ltd., incorporated on November 10, 2023, is a non-operating financial holding company and a Special Purpose Vehicle. Its turnover for FY 2023-24, 2024-25, and 2025-26 has been nil. The investment is considered a related party transaction but is conducted on an arm's length basis. The company stated that it will inform the stock exchanges about further tranches of equity investments as they are made.
